연구용
제품 번호: S1705
화학 구조
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| human T47D cells | Function assay | 20 h | Activation of progesterone receptor in human T47D cells after 20 hrs by PRE-tagged luciferase reporter gene assay, EC50=0.1 nM | |||
| CV-1 cells | Function assay | Effective concentration for half-maximal activation of human progesterone receptor expressed in CV-1 cells, EC50=1.5 nM | ||||
| HEK293 cells | Function assay | Agonist activity at human PRGR expressed in HEK293 cells by luciferase reporter gene assay, EC50=2 nM | ||||
| SF-12 cells | Function assay | Displacement of DHT from human androgen receptor expressed in baculovirus SF-12 cells, Ki=9.5 nM | ||||
| CHO cells | Function assay | Agonist activity at human TGR5 expressed in CHO cells by luciferase assay, EC50=2.77 μM | ||||
| human K562/R7 cells | Function assay | 1 μM | 72 h | Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay, IC50=10.6 μM | ||
| A2780 cells | Function assay | Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay, IC50=47.863 μM | ||||
| HeLa cells | Cytotoxicity assay | Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis | ||||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 314.46 | 화학식 | C21H30O2 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 57-83-0 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NSC 64377, Pregn-4-ene-3,20-dione,NSC 9704 | Smiles | CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C | ||
|
In vitro |
DMSO
: 40 mg/mL
(127.2 mM)
Ethanol : 20 mg/mL Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
progestogen Receptor
|
|---|---|
| 시험관 내(In vitro) |
Progesterone has biphasic effects on proliferation of breast cancer cells; it stimulates growth in the first cell cycle, then arrests cells at G1/S of the second cycle accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21. This compound-mediated transcription is further prevented by overexpression of E1A, suggesting that CBP/p300 is required. It drives a series of events where luminal cells probably provide Wnt4 and RANKL signals to basal cells which in turn respond by upregulating their cognate receptors, transcriptional targets and cell cycle markers. This hormone treatment increases the sensitivity of cortical synaptoneurosomes to GABA (i.e., decreased the EC50) and increases the maximal efficacy with which GABA stimulated Cl- transport (i.e., increased the Emax). |
| 생체 내(In vivo) |
Progesterone blocks the beneficial effect of estrogen on Abeta accumulation but not on behavioral performance in female 3xTg-AD mice. This compound significantly reduces tau hyperphosphorylation when administered both alone and in combination with estrogen. Progesterone-treated rats are less impaired on a Morris water maze spatial navigation task than rats treated with the oil vehicle. This compound-treated rats also show less neuronal degeneration 21 days after injury in the medial dorsal thalamic nucleus, a structure that has reciprocal connections with the contused area. |
참조 |
|
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT06089395 | Not yet recruiting | Poor Ovarian Response |
Shi Yun|Capital Medical University|Dongzhimen Hospital Beijing |
June 1 2024 | Early Phase 1 |
| NCT06359457 | Not yet recruiting | Primary Dysmenorrhea |
Cairo University |
May 2024 | -- |
| NCT06334315 | Not yet recruiting | Contraception|Pharmacogenomic Drug Interaction |
Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
May 2024 | Phase 4 |